Maravai LifeSciences Holdings, Inc.

Equities

MRVI

US56600D1072

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:00:59 16/07/2024 pm IST 5-day change 1st Jan Change
8.905 USD +1.66% Intraday chart for Maravai LifeSciences Holdings, Inc. +17.44% +35.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Goldman Sachs Trims Price Target on Maravai LifeSciences to $7 From $8, Maintains Neutral Rating MT
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 3000E Value Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 1000 Dynamic Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Midcap Growth Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 1000 Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) added to Russell 2000 Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 1000 Value Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Midcap Value Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 3000 Value Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 2500 Value Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) added to Russell 2000 Growth Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Midcap Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) added to Russell 2000 Dynamic Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 1000 Growth Index CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Small Cap Comp Value Index CI
Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024 CI
Transcript : Maravai LifeSciences Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM
Transcript : Maravai LifeSciences Holdings, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 03:35 PM
UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating MT
Baird Adjusts Price Target on Maravai LifeSciences to $10 From $8, Keeps Outperform Rating MT
Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Reports Q1 Revenue $64.2M, vs. Street Est of $60.5M MT
Transcript : Maravai LifeSciences Holdings, Inc., Q1 2024 Earnings Call, May 08, 2024
Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024 CI
Maravai LifeSciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego MT
Chart Maravai LifeSciences Holdings, Inc.
More charts
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
8.76 USD
Average target price
10.75 USD
Spread / Average Target
+22.72%
Consensus
  1. Stock Market
  2. Equities
  3. MRVI Stock
  4. News Maravai LifeSciences Holdings, Inc.
  5. Goldman Sachs Trims Price Target on Maravai LifeSciences to $7 From $8, Maintains Neutral Rating